Publications by authors named "Mark Demitrack"

Claim this Profile
O
Oliceridine for postoperative pain and opioid-related complications: The intravenous oliceridine and opioid-related complications (VOLITION) prospective cohort study.
Daniel I Sessler, Sabry Ayad, Omer Bakal, Nataya S Disher, Jorge Araujo Duran, Mark A Demitrack

J Clin Anesth· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TMS and EEG Pharmacodynamic Effects of a Selective Sphingosine-1-Phosphate Subtype 1 Receptor Agonist on Cortical Excitability in Healthy Subjects.
Catherine M K E de Cuba, Annika A de Goede, Erica S Klaassen, Marije E Otto, Robert J Doll, Mark A Demitrack

Clin Pharmacol Ther· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Multisite, 6-Month, Open-Label Study of Maintenance Transcranial Magnetic Stimulation for Adolescents with Treatment-Resistant Depression.
Juan F Garzon, Ahmed Z Elmaadawi, Scott T Aaronson, G Randolph Schrodt, Richard C Holbert, Mark A Demitrack

J Child Adolesc Psychopharmacol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurocognitive Effect of Biased µ-Opioid Receptor Agonist Oliceridine, a Utility Function Analysis and Comparison with Morphine.
Laurence Moss, Hemme Hijma, Mark Demitrack, Jessica Kim, Geert Jan Groeneveld

Anesthesiology· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Respiratory Effects of Biased Ligand Oliceridine in Older Volunteers: A Pharmacokinetic-Pharmacodynamic Comparison with Morphine.
Pieter Simons, Rutger van der Schrier, Maarten van Lemmen, Simone Jansen, Kiki W K Kuijpers, Mark A Demitrack

Anesthesiology· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurostructural Differences in Adolescents With Treatment-Resistant Depression and Treatment Effects of Transcranial Magnetic Stimulation.
Bhedita J Seewoo, Jennifer Rodger, Mark A Demitrack, Karen L Heart, John D Port

Int J Neuropsychopharmacol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budget impact and pharmacy costs with targeted use of oliceridine for postsurgical pain in patients at high risk of opioid-related adverse events.
Kit N Simpson, Michael J Fossler, Linda Wase, Mark A Demitrack, Todd L Wandstrat

Expert Rev Pharmacoecon Outcomes Res· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oliceridine Exhibits Improved Tolerability Compared to Morphine at Equianalgesic Conditions: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Controlled Trials.
Gregory B Hammer, Ashish K Khanna, Cathy Michalsky, Linda Wase, Mark A Demitrack

Pain Ther· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intracellular uptake of agents that block the hERG channel can confound the assessment of QT interval prolongation and arrhythmic risk.
Alexander Burashnikov, Hector Barajas-Martinez, Robert Cox, Mark A Demitrack, Michael J Fossler

Heart Rhythm· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness and cost-benefit analysis of oliceridine in the treatment of acute pain.
Kit N Simpson, Michael J Fossler, Linda Wase, Mark A Demitrack

J Comp Eff Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oliceridine is Associated with Reduced Risk of Vomiting and Need for Rescue Antiemetics Compared to Morphine: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Controlled Trials.
Timothy L Beard, Cathy Michalsky, Keith A Candiotti, Paul Rider, Linda Wase, Mark A Demitrack

Pain Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low Incidence of Opioid-Induced Respiratory Depression Observed with Oliceridine Regardless of Age or Body Mass Index: Exploratory Analysis from a Phase 3 Open-Label Trial in Postsurgical Pain.
Marek Brzezinski, Gregory B Hammer, Keith A Candiotti, Sergio D Bergese, Peter H Pan, Mark A Demitrack

Pain Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low Incidence of Postoperative Respiratory Depression with Oliceridine Compared to Morphine: A Retrospective Chart Analysis.
Sergio Bergese, Richard Berkowitz, Paul Rider, Martin Ladouceur, Suzanne Griffith, Mark A Demitrack

Pain Res Manag· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Left prefrontal transcranial magnetic stimulation for treatment-resistant depression in adolescents: a double-blind, randomized, sham-controlled trial.
Paul E Croarkin, Ahmed Z Elmaadawi, Scott T Aaronson, G Randolph Schrodt, Richard C Holbert, Mark A Demitrack

Neuropsychopharmacology· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit and Risk Evaluation of Biased μ-Receptor Agonist Oliceridine versus Morphine.
Albert Dahan, C Jan van Dam, Marieke Niesters, Monique van Velzen, Michael J Fossler, Mark A Demitrack

Anesthesiology· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Incidence of Opioid-Induced Respiratory Depression Associated with Oliceridine and Morphine as Measured by the Frequency and Average Cumulative Duration of Dosing Interruption in Patients Treated for Acute Postoperative Pain.
Sabry Ayad, Mark A Demitrack, David A Burt, Cathy Michalsky, Linda Wase

Clin Drug Investig· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects.
Michael J Fossler, Virginia Schmith, Stephen A Greene, Lauren Lohmer, Michael S Kramer, Mark A Demitrack

CNS Drugs· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-Resistant Depression in Adolescents: Clinical Features and Measurement of Treatment Resistance.
Jeffrey R Strawn, Scott T Aaronson, Ahmed Z Elmaadawi, G Randolph Schrodt, Richard C Holbert, Mark A Demitrack

J Child Adolesc Psychopharmacol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
APOLLO-2: A Randomized, Placebo and Active-Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein-Biased Ligand at the μ-Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty.
Neil K Singla, Franck Skobieranda, David G Soergel, Monica Salamea, David A Burt, Mark A Demitrack

Pain Pract· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form (ATHF-SF).
Harold A Sackeim, Scott T Aaronson, Mark T Bunker, Charles R Conway, Mark A Demitrack

J Psychiatr Res· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can Medication Free, Treatment-Resistant, Depressed Patients Who Initially Respond to TMS Be Maintained Off Medications? A Prospective, 12-Month Multisite Randomized Pilot Study.
Noah S Philip, David L Dunner, Sheila M Dowd, Scott T Aaronson, David G Brock, Mark A Demitrack

Brain Stimul· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to "Can Medication Free, Treatment-Resistant, Depressed Patients Who Initially Respond to TMS Be Maintained Off Medications? A Prospective, 12-Month Multisite Randomized Pilot Study" [Brain Stimulation 9 (2016) 251-257].
Noah S Philip, David L Dunner, Sheila M Dowd, Scott T Aaronson, David G Brock, Mark A Demitrack

Brain Stimul· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period.
David L Dunner, Scott T Aaronson, Harold A Sackeim, Philip G Janicak, Linda L Carpenter, Mark A Demitrack

J Clin Psychiatry· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of quality of life outcome measures in clinical practice.
Philip G Janicak, David L Dunner, Scott T Aaronson, Linda L Carpenter, Terrence A Boyadjis, Mark A Demitrack

CNS Spectr· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Left dorsolateral prefrontal transcranial magnetic stimulation (TMS): sleep factor changes during treatment in patients with pharmacoresistant major depressive disorder.
Peter B Rosenquist, Andrew Krystal, Karen L Heart, Mark A Demitrack, W Vaughn McCall

Psychiatry Res· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis